Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × Neoplasms × Doxorubicin × Clear all

Phase

Status

Completed 23 Active not recruiting 7 Terminated 5 Recruiting 4 Withdrawn 1 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 9 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma 7 Triple Negative Breast Neoplasms 4 Lymphoma, Mantle-Cell 3 Lymphoma, Follicular 3 Carcinoma, Hepatocellular 3 Waldenstrom Macroglobulinemia 2 Sarcoma 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Lymphoma, Non-Hodgkin 2 Lymphoma, Large-Cell, Anaplastic 2 Lymphoma, Extranodal NK-T-Cell 2 Dendritic Cell Sarcoma, Interdigitating 2 Vomiting 1 Sezary Syndrome 1 Platinum-Refractory Fallopian Tube Carcinoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neoplasms 1 Neoplasm Metastasis 1 Nausea 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Primary Effusion 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, B-Cell, Marginal Zone 1

Interventions

Cisplatin 9 pembrolizumab 5 Radiosurgery 5 Gemcitabine 5 Taxes 4 Paclitaxel 4 Dexamethasone 4 trametinib 3 ibrutinib 3 Surveys and Questionnaires 3 Standard of Care 3 Radiotherapy 3 Nivolumab 3 Magnetic Resonance Spectroscopy 3 Fluorouracil 3 Carboplatin 3 Ascorbic Acid 3 tocilizumab 2 pazopanib 2 obinutuzumab 2 naquotinib 2 lenvatinib 2 fludarabine 2 enzalutamide 2 Trastuzumab 2 Surgical Procedures, Operative 2 SS1(dsFv)PE38 2 Radiation Dose Hypofractionation 2 Pemetrexed 2 Ondansetron 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00124956 2017-09-11

Doxorubicin Pharmacokinetic (PK) Study

Boston Children's Hospital

Phase 1/2 Withdrawn

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡